Study finds higher hospital admissions, complications, and mortality rates among patients with increased A1c.

Studies find greater risk reduction following treatment of patients with dyslipidemia.

Most important mediator due to changes in markers of plasma volume.

Secondary analysis evaluates effect of Women’s Health Initiative dietary intervention.

Guest Post by David Kliff, Editor, Diabetic Investor
Senseonics has taken their Eversense implantable CGM before an FDA panel, and Bigfoot has announced they have closed their series B $55 million financing round. The FDA has approved Dexcom’s G6 system, pushing shares in the company higher in early trading. And while they didn’t announce anything recently, our friends at Tandem are feeling the love as shares continue to surge higher in anticipation of their new system, which has low glucose suspend.

Mr. Hernandez's labs are notable for A1C 7.5, FPG 137 mg/dL, LDL-cholesterol 190 mg/dL, HDL-cholesterol 38 mg/dL, and triglycerides 232 mg/dL. You discuss his lab results, his diagnosis, and how to manage diabetes, then you make referrals to the appropriate diabetes team clinicians. You start Mr. Hernandez on metformin, lifestyle modifications, an ACE inhibitor, and a statin. What clinical parameters are you looking to achieve? A. A1C less than 7%, BP less than 130/80 mmHg, LDL less than 100 mg/dL B. A1C less than 7%, BP less than 130/90 mmHg, LDL less than 100 mg/dL C. A1C less than 7%, BP less than 140/80 mmHg, LDL less than 100 mg/dL D. A1C less than 7%, BP less than 140/90 mmHg, LDL less than 150 mg/dL Follow the link for the answer.

Do you prescribe sulfonylureas?

As I was reviewing this months SGLT-2 Therapy edition I was reminded of how much this class of drugs has opened up dialogues on patient care in multiple disease states. With the older diabetes medications we talked A1c, Fasting, or Postprandial; all related to diabetes and there was not much …

When we talk to patients about prediabetes, one of the topics of discussion is likely to be about insulin resistance. However, what we are usually describing is glucose resistance. The lecture usually goes something like this: “If you eat too much sugar, then your cells get filled with the sugar …

In part 4 of this Exclusive Interview, Dr. Swapnil N. Rajpathak talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about his interest in the comparative analysis of various drug classes and their real-world implications.